Despite notable on-treatment differences in the peripheral blood immune profile between treatment arms, i.e., NIVO monotherapy was associated with a lower magnitude of increase in peripheral immune cells, such as CD8+ T cells, than BEMPEG + NIVO, changes in tumor biomarkers in the TME from baseline to C1D21 were similar between treatment arms. The gene discussed is CD8A; the disease is neoplasm.